Axogen (AXGN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $34.62, -2.83% vs the prior close of $35.63.
- Volume 1.13M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AXGN dips 2.8% to $34.62, a 6-month low. Closed at $34.62, -2.83% vs the prior close of $35.63. Day range $34.40–$35.65, opened at $35.63.
AXGN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AXGN dips 2.8% to $34.62, a 6-month low
- Closed at $34.62, -2.83% vs the prior close of $35.63. Day range $34.40–$35.65, opened at $35.63.
- Volume was 1.13M shares, 0.9x its 50-day average of 1.22M.
- Price is -22.1% vs its 50-day average ($44.41) and -11.5% vs its 200-day average ($39.14).
- 52-week range $16.24–$52.91; today's close sits at 50% of that range, 34.6% below the 52-week high.
Oct 15, 2026 — AXGN rises 1.4% to $35.63
- Closed at $35.63, +1.39% vs the prior close of $35.14. Day range $35.14–$36.42, opened at $35.14.
- Volume was 986.00K shares, 0.8x its 50-day average of 1.22M.
- Price is -20.1% vs its 50-day average ($44.61) and -8.9% vs its 200-day average ($39.13).
- 52-week range $15.94–$52.91; today's close sits at 53% of that range, 32.7% below the 52-week high.
Oct 14, 2026 — AXGN dips 2.8% to $35.14, a 3-month low
- Closed at $35.14, -2.85% vs the prior close of $36.17. Day range $35.03–$36.55, opened at $35.91.
- Volume was 1.17M shares, 1.0x its 50-day average of 1.22M.
- Price is -21.6% vs its 50-day average ($44.80) and -10.2% vs its 200-day average ($39.12).
- 52-week range $15.27–$52.91; today's close sits at 53% of that range, 33.6% below the 52-week high.
Oct 13, 2026 — AXGN dips 2.5% to $36.17
- Closed at $36.17, -2.53% vs the prior close of $37.11. Day range $35.83–$37.40, opened at $37.20.
- Volume was 2.14M shares, 1.8x its 50-day average of 1.21M.
- Price is -19.7% vs its 50-day average ($45.02) and -7.5% vs its 200-day average ($39.10).
- 52-week range $15.27–$52.91; today's close sits at 56% of that range, 31.6% below the 52-week high.
Oct 12, 2026 — AXGN rises 2.7% to $37.11
- Closed at $37.11, +2.71% vs the prior close of $36.13. Day range $35.72–$37.31, opened at $36.80.
- Volume was 1.61M shares, 1.3x its 50-day average of 1.20M.
- Price is -17.9% vs its 50-day average ($45.21) and -5.1% vs its 200-day average ($39.09).
- 52-week range $15.27–$52.91; today's close sits at 58% of that range, 29.9% below the 52-week high.
Oct 9, 2026 — AXGN ends flat (-0.1%) to $36.13
- Closed at $36.13, -0.14% vs the prior close of $36.18. Day range $35.60–$36.80, opened at $36.35.
- Volume was 929.80K shares, 0.8x its 50-day average of 1.21M.
- Price is -20.3% vs its 50-day average ($45.31) and -7.5% vs its 200-day average ($39.07).
- 52-week range $15.27–$52.91; today's close sits at 55% of that range, 31.7% below the 52-week high.
Oct 8, 2026 — AXGN rises 0.4% to $36.18
- Closed at $36.18, +0.39% vs the prior close of $36.04. Day range $35.44–$36.32, opened at $35.98.
- Volume was 1.38M shares, 1.1x its 50-day average of 1.23M.
- Price is -20.3% vs its 50-day average ($45.41) and -7.3% vs its 200-day average ($39.05).
- 52-week range $15.27–$52.91; today's close sits at 56% of that range, 31.6% below the 52-week high.
Oct 7, 2026 — AXGN dips 0.7% to $36.04, a 3-month low, 8 down days in a row
- Closed at $36.04, -0.74% vs the prior close of $36.31. Day range $35.83–$36.88, opened at $36.31.
- Volume was 1.60M shares, 1.3x its 50-day average of 1.23M.
- Price is -20.8% vs its 50-day average ($45.52) and -7.7% vs its 200-day average ($39.03).
- 52-week range $15.27–$52.91; today's close sits at 55% of that range, 31.9% below the 52-week high.
- That makes 8 straight losses.
Oct 6, 2026 — AXGN dips 2.4% to $36.31, a 3-month low on 2.0x normal volume
- Closed at $36.31, -2.44% vs the prior close of $37.22. Day range $35.82–$37.61, opened at $37.23.
- Volume was 2.35M shares, 2.0x its 50-day average of 1.20M — unusually heavy trading.
- Price is -20.4% vs its 50-day average ($45.62) and -6.9% vs its 200-day average ($39.01).
- 52-week range $15.27–$52.91; today's close sits at 56% of that range, 31.4% below the 52-week high.
- That makes 7 straight losses.
Oct 5, 2026 — AXGN dips 0.5% to $37.22, a 3-month low on 1.9x normal volume
- Closed at $37.22, -0.45% vs the prior close of $37.39. Day range $36.79–$38.27, opened at $37.47.
- Volume was 2.19M shares, 1.9x its 50-day average of 1.17M — unusually heavy trading.
- Price is -18.6% vs its 50-day average ($45.72) and -4.5% vs its 200-day average ($38.98).
- 52-week range $15.27–$52.91; today's close sits at 58% of that range, 29.7% below the 52-week high.
- That makes 6 straight losses.
Oct 2, 2026 — AXGN slides 6.3% to $37.39, a 3-month low on 2.8x normal volume
- Closed at $37.39, -6.34% vs the prior close of $39.92. Day range $36.97–$39.92, opened at $39.92.
- Volume was 3.10M shares, 2.8x its 50-day average of 1.13M — unusually heavy trading.
- Price is -18.3% vs its 50-day average ($45.76) and -4.0% vs its 200-day average ($38.94).
- 52-week range $15.27–$52.91; today's close sits at 59% of that range, 29.3% below the 52-week high.
- That makes 5 straight losses.
AXGN latest news & SEC filings
Every SEC filing by or about AXGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 10, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 10, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tyndall Joseph A. sold 3,500 shares at $49.70 (≈$173.95K) on Sep 2, 2026
- Tyndall Joseph A. sold 3,500 shares at $49.70 (≈$173.95K) on Sep 2, 2026
- Tyndall Joseph A. sold 3,500 shares at $49.70 (≈$173.95K) on Sep 2, 2026
- Tyndall Joseph A. sold 3,500 shares at $49.70 (≈$173.95K) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Began Marc A sold 67,500 shares at $47.35 (≈$3.20M) on Aug 10, 2026
- Began Marc A sold 67,500 shares at $47.35 (≈$3.20M) on Aug 10, 2026
- Began Marc A sold 67,500 shares at $47.35 (≈$3.20M) on Aug 10, 2026
- Began Marc A sold 67,500 shares at $47.35 (≈$3.20M) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wendell Amy Mcbride sold 13,353 shares at $48.42 (≈$646.55K) on Aug 11, 2026
- Wendell Amy Mcbride sold 13,353 shares at $48.42 (≈$646.55K) on Aug 11, 2026
- Wendell Amy Mcbride sold 13,353 shares at $48.42 (≈$646.55K) on Aug 11, 2026
- Wendell Amy Mcbride sold 13,353 shares at $48.42 (≈$646.55K) on Aug 11, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Weiler Kathy Johnson sold 14,150 shares at $45.30 (≈$641.00K) on Aug 7, 2026
- Weiler Kathy Johnson sold 14,150 shares at $45.30 (≈$641.00K) on Aug 7, 2026
- Weiler Kathy Johnson sold 14,150 shares at $45.30 (≈$641.00K) on Aug 7, 2026
- Weiler Kathy Johnson sold 14,150 shares at $45.30 (≈$641.00K) on Aug 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 31, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $69.73M (prior year $56.66M) (+23.1% vs Jun 30, 2025)
- Net income: -$1.52M (prior year $579.00K) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.03 (prior year $0.01) (loss widened vs Jun 30, 2025)
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade AXGN
- Last results release: Jul 29, 2026 (8-K Item 2.02). Previous ones: Apr 28, 2026, Feb 24, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 28, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.04% (largest 6.3%).
- Liquidity: about 1.47M shares (≈$50.82M) trade per day on average.
- 52-week position: $34.62 vs a range of $16.24–$52.91 (50% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Joseph A. Tyndall sold 3,500 shares on Sep 2, 2026.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 10, 2026; 10-Q Jul 29, 2026.
- Share count: 53.76M shares outstanding (Jul 27, 2026), +16.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Electromedical & Electrotherapeutic Apparatus.
AXGN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 35.63 | 35.65 | 34.40 | 34.62 | 1.13M |
| Oct 15, 2026 | 35.14 | 36.42 | 35.14 | 35.63 | 986.00K |
| Oct 14, 2026 | 35.91 | 36.55 | 35.03 | 35.14 | 1.17M |
| Oct 13, 2026 | 37.20 | 37.40 | 35.83 | 36.17 | 2.14M |
| Oct 12, 2026 | 36.80 | 37.31 | 35.72 | 37.11 | 1.61M |
| Oct 9, 2026 | 36.35 | 36.80 | 35.60 | 36.13 | 929.80K |
| Oct 8, 2026 | 35.98 | 36.32 | 35.44 | 36.18 | 1.38M |
| Oct 7, 2026 | 36.31 | 36.88 | 35.83 | 36.04 | 1.60M |
| Oct 6, 2026 | 37.23 | 37.61 | 35.82 | 36.31 | 2.35M |
| Oct 5, 2026 | 37.47 | 38.27 | 36.79 | 37.22 | 2.19M |
| Oct 2, 2026 | 39.92 | 39.92 | 36.97 | 37.39 | 3.10M |
| Oct 1, 2026 | 41.56 | 42.20 | 39.68 | 39.92 | 1.60M |
| Sep 30, 2026 | 42.35 | 43.09 | 41.75 | 41.92 | 1.09M |
| Sep 29, 2026 | 43.67 | 43.79 | 41.76 | 42.44 | 1.41M |
| Sep 28, 2026 | 43.23 | 43.94 | 42.46 | 43.36 | 885.50K |
| Sep 25, 2026 | 43.61 | 44.68 | 43.05 | 43.39 | 1.22M |
| Sep 24, 2026 | 43.18 | 43.95 | 42.55 | 43.32 | 796.60K |
| Sep 23, 2026 | 44.54 | 44.84 | 43.25 | 43.32 | 1.25M |
| Sep 22, 2026 | 46.17 | 47.00 | 44.00 | 44.54 | 1.33M |
| Sep 21, 2026 | 44.82 | 46.58 | 44.32 | 45.93 | 1.20M |
About Axogen
Axogen (AXGN) is listed on the Nasdaq and classified by the SEC under “Electromedical & Electrotherapeutic Apparatus”. Its business address is in ALACHUA, FL. State of incorporation: MN. Fiscal year ends December 31. SEC CIK 805928.
AXGN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| William P. Mr. Burke | Director | Jun 26, 2026 |
| John Johnson | Director | Jun 26, 2026 |
| Alan M Levine | Director | Jun 26, 2026 |
| Paul Thomas | Director | Jun 26, 2026 |
| Joseph A. Tyndall | Director | Sep 4, 2026 |
| Kathy Johnson Weiler | Director | Aug 11, 2026 |
| Amy Mcbride Wendell | Director | Aug 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Marc A Began | EVP & General Counsel | Aug 12, 2026 |
| Michael D Dale | Chief Executive Officer | Feb 27, 2026 |
| Erick Wayne Devinney | Chief Innovation Officer | Mar 18, 2026 |
| Lindsey Marie Hartley | CFO | May 8, 2026 |
| Jens Kemp | Chief Marketing Officer | May 8, 2026 |
| Doris Quackenbush | Sales VP | May 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Joseph A. Tyndall | Sale | 3,500 | $49.70 |
| Sep 2, 2026 | Joseph A. Tyndall | Sale | 3,500 | $49.70 |
| Sep 2, 2026 | Joseph A. Tyndall | Sale | 3,500 | $49.70 |
| Sep 2, 2026 | Joseph A. Tyndall | Sale | 3,500 | $49.70 |
| Aug 11, 2026 | Amy Mcbride Wendell | Sale | 13,353 | $48.42 |
| Aug 11, 2026 | Amy Mcbride Wendell | Sale | 13,353 | $48.42 |
| Aug 11, 2026 | Amy Mcbride Wendell | Sale | 13,353 | $48.42 |
| Aug 11, 2026 | Amy Mcbride Wendell | Sale | 13,353 | $48.42 |
| Aug 10, 2026 | Marc A Began | Sale | 67,500 | $47.35 |
| Aug 10, 2026 | Marc A Began | Sale | 67,500 | $47.35 |
| Aug 10, 2026 | Marc A Began | Sale | 67,500 | $47.35 |
| Aug 10, 2026 | Marc A Began | Sale | 67,500 | $47.35 |
| Aug 7, 2026 | Kathy Johnson Weiler | Sale | 14,150 | $45.30 |
| Aug 7, 2026 | Kathy Johnson Weiler | Sale | 14,150 | $45.30 |
| Aug 7, 2026 | Kathy Johnson Weiler | Sale | 14,150 | $45.30 |
AXGN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $225.21M | $-15.70M | -0.34 | $812.00K |
| Dec 31, 2024 | $187.34M | $-9.96M | -0.23 | $4.54M |
| Dec 31, 2023 | $159.01M | $-21.72M | -0.51 | $-5.72M |
| Dec 31, 2022 | $138.58M | $-28.95M | -0.69 | $-16.07M |
| Dec 31, 2021 | $127.36M | $-26.98M | -0.65 | $-13.40M |
Latest balance sheet: total assets $304.86M, total liabilities $48.61M, cash $94.57M (as of Jun 30, 2026).
AXGN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 29, 2026 | 8-K Item 2.02 (results) | $41.37 |
| Apr 28, 2026 | 8-K Item 2.02 (results) | $41.99 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $32.50 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $31.55 |
| Oct 29, 2025 | 8-K Item 2.02 (results) | $22.25 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $13.72 |
| May 8, 2025 | 8-K Item 2.02 (results) | $12.59 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $20.11 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $18.05 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $13.27 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Electromedical & Electrotherapeutic Apparatus
Medtronic (MDT)Integer (ITGR)TransMedics (TMDX)LivaNova (LIVN)Nexalin Technology (NXL)Conmed (CNMD)Ceribell (CBLL)InMode (INMD)Electromed (ELMD)Hyperfine (HYPR)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AXGN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.